Overview

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-12-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb